<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Febri Kurniawati</style></author><author><style face="normal" font="default" size="100%">Sony Wibisono Mudjanarko</style></author><author><style face="normal" font="default" size="100%">Soebagijo Adi Soelistijo</style></author><author><style face="normal" font="default" size="100%">Titong Sugihartono</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Association of Triglyceride and Glucose Index with Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus Patients</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Hepatic steatosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Insulin resistance</style></keyword><keyword><style  face="normal" font="default" size="100%">NAFLD</style></keyword><keyword><style  face="normal" font="default" size="100%">TyG index</style></keyword><keyword><style  face="normal" font="default" size="100%">Type 2 diabetes mellitus</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">October 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">1077- 1080</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Non-alcoholic fatty liver disease (NAFLD) is significantly linked to obesity, insulin resistance (IR), metabolic syndrome, and type 2 diabetes (T2DM). There isn't a single biomarker used to diagnose NAFLD. &lt;strong&gt;Objectives:&lt;/strong&gt; Analyzing the association between triglyceride and glucose index (TyG) with NAFLD in T2DM. &lt;strong&gt;Methods: &lt;/strong&gt;This cross-sectional study aimed to assess the efficacy of TyG as a potential NAFLD biomarker. The study was conducted on 103 diabetes outpatient clinics at the Dr. Soetomo General Academic Hospital from August to October 2023. Sixty-seven subjects experienced steatosis, while those who did not experience steatosis were 36. The statistical analysis used in this study is binary logistic regression with p &amp;lt;0.05. &lt;strong&gt;Results:&lt;/strong&gt; The receiver operating characteristic curves (ROC) analysis showed a TyG cut-off value of 9.334 (AUC = 0.660). Analysis of the risk of TyG on the incidence of steatosis was carried out using binary logistic regression. The results showed that TyG was a significant risk factor for steatosis. Patients with a TyG value above 9.334 risk developing steatosis 3.567 times greater than patients with a TyG value below 9.334 (OR 95% = 1.373 – 9.270, p = 0.009). &lt;strong&gt;Conclusion: &lt;/strong&gt;A significant association between TyG and NAFLD in T2DM patients, which the TyG index may be a more effective, valuable, and uncomplicated measure for detecting and controlling NAFLD.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">1077</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Febri Kurniawati&lt;sup&gt;1,2&lt;/sup&gt;, Sony Wibisono Mudjanarko&lt;sup&gt;3,4*&lt;/sup&gt;, Soebagijo Adi Soelistijo&lt;sup&gt;3,4&lt;/sup&gt;, Titong Sugihartono&lt;sup&gt;3,5&lt;/sup&gt; &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Internal Medicine Subspecialty Study Program, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Division of Gastroentero-Hepatology, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nur Sofiatul Aini</style></author><author><style face="normal" font="default" size="100%">Arif Nur Muhammad Ansori</style></author><author><style face="normal" font="default" size="100%">Viol Dhea Kharisma</style></author><author><style face="normal" font="default" size="100%">Muhammad Farraz Syadzha</style></author><author><style face="normal" font="default" size="100%">Muhammad Hermawan Widyananda</style></author><author><style face="normal" font="default" size="100%">Ahmad Affan Ali Murtadlo</style></author><author><style face="normal" font="default" size="100%">Rasyadan Taufiq Probojati</style></author><author><style face="normal" font="default" size="100%">Md. Emdad Ullah</style></author><author><style face="normal" font="default" size="100%">Sin War Naw</style></author><author><style face="normal" font="default" size="100%">Vikash Jakhmola</style></author><author><style face="normal" font="default" size="100%">Rahadian Zainul</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Potential Roles of Purslane (Portulaca oleracea L.) as Antimetabolic Syndrome: A Review</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Body weight</style></keyword><keyword><style  face="normal" font="default" size="100%">Insulin resistance</style></keyword><keyword><style  face="normal" font="default" size="100%">Metabolic syndrome</style></keyword><keyword><style  face="normal" font="default" size="100%">Obesity.</style></keyword><keyword><style  face="normal" font="default" size="100%">Portulaca oleracea</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">710-714</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;The number of cases of obesity and type 2 diabetes mellitus (T2DM) is part of the metabolic syndrome case. Purslane (&lt;em&gt;Portulaca oleracea&lt;/em&gt; L.) is a plant that has been clinically tested and has the potential to prevent and treat metabolic syndrome as well as pathogenic and pathophysiological activities that cause disease. The aim of this study is to discuss and conclude information regarding the activity and use of purslane (&lt;em&gt;P. oleracea&lt;/em&gt;) as an antimetabolic. This review article is based on scientific publications found on Google Scholar and PubMed databases using the keywords of “Portulaca obesity”, “&lt;em&gt;Portulaca &lt;/em&gt;overweight”, “Portulaca dyslipidemia”, and “&lt;em&gt;Portulaca&lt;/em&gt; metabolic syndrome”. This plant acts on numerous pathways in the metabolic syndrome such as reduction of lipids, blood sugar, body weight and total cholesterol. Purslane (&lt;em&gt;P. oleracea&lt;/em&gt;) can be used as a candidate for a new herbal plant as an anti-metabolic syndrome.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Review Article</style></work-type><accession-num><style face="normal" font="default" size="100%">30</style></accession-num><section><style face="normal" font="default" size="100%">710</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Nur Sofiatul Aini&lt;sup&gt;1&lt;/sup&gt;, Arif Nur Muhammad Ansori&lt;sup&gt;2&lt;/sup&gt;, Viol Dhea Kharisma&lt;sup&gt;3,4&lt;/sup&gt;, Muhammad Farraz Syadzha&lt;sup&gt;4&lt;/sup&gt;, Muhammad Hermawan Widyananda&lt;sup&gt;3,4&lt;/sup&gt;, Ahmad Affan Ali Murtadlo&lt;sup&gt;4&lt;/sup&gt;, Rasyadan Taufiq Probojati&lt;sup&gt;4&lt;/sup&gt;, Md. Emdad Ullah&lt;sup&gt;5&lt;/sup&gt;, Sin War Naw&lt;sup&gt;6&lt;/sup&gt;, Vikash Jakhmola&lt;sup&gt;7&lt;/sup&gt;, Rahadian Zainul&lt;sup&gt;8,9,*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Faculty of Mathematics and Natural Sciences, State University of Surabaya, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Professor Nidom Foundation, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Faculty of Mathematics and Natural Sciences, Brawijaya University, Malang, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Division of Molecular Biology and Genetics, Generasi Biologi Indonesia Foundation, Gresik, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Department of Chemistry, Mississippi State University, Mississippi State, UNITED STATES.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;6&lt;/sup&gt;Department of Chemistry, Myitkyina University, Myitkyina, MYANMAR.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;7&lt;/sup&gt;Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, INDIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;8&lt;/sup&gt;Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Negeri Padang, Padang, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;9&lt;/sup&gt;Center for Advanced Material Processing, Artificial Intelligence, and Biophysic Informatics (CAMPBIOTICS), Universitas Negeri Padang, Padang, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Raysa Y. Pratiwi</style></author><author><style face="normal" font="default" size="100%">Berna Elya</style></author><author><style face="normal" font="default" size="100%">Heri Setiawan</style></author><author><style face="normal" font="default" size="100%">Atini Solawati</style></author><author><style face="normal" font="default" size="100%">Rosmalena</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Alterations in Body Weight, Blood Glucose Levels, and Lipid Profiles in High-Fat Diet-Low Dose Streptozotocin-Induced Diabetic Rats</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Diabetes</style></keyword><keyword><style  face="normal" font="default" size="100%">Diabetic animal model</style></keyword><keyword><style  face="normal" font="default" size="100%">High-fat diet</style></keyword><keyword><style  face="normal" font="default" size="100%">Insulin resistance</style></keyword><keyword><style  face="normal" font="default" size="100%">Low-dose streptozotocin</style></keyword><keyword><style  face="normal" font="default" size="100%">Stable diabetes type 2 profile.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">December 2021</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">13</style></volume><pages><style face="normal" font="default" size="100%">1562-1567</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;New preventive and therapeutic strategies to treat Type 2 diabetes (T2D) continue to be pursued, the complexity of this disease makes it imperative to establish preclinical animal models which must provide accurate similarities to the pathogenesis of diabetes in humans. Making a diabetic animal model using rats with high-fat diet (HFD)-streptozotocin (STZ) induction is popular because it is relatively low cost and simple. &lt;strong&gt;Objectives:&lt;/strong&gt; This study aims to analyse the changes in body weight, blood glucose, and lipid profiles that occur in diabetic rat models created by induction of HFD in combination with lowdose STZ. &lt;strong&gt;Methods: &lt;/strong&gt;This study used forty male Sprague-Dawley rats (200-240 g). After the adaptation period, thirty rats were fed with HFD for 28 days (DM group), while the other ten rats continued to be fed with standard feed (NC group). After then, diabetes was induced to the DM group by low-dose STZ (35 mg/kg BW). The body weight of the rats was measured before and after diet manipulation periods. Blood samples were taken before and after STZ induction to determine lipid profiles and blood glucose levels.&lt;strong&gt; Results:&lt;/strong&gt; During the diet manipulation period, the HFD group experienced a significantly greater weight gain, higher blood glucose levels, and cholesterol (TC) levels. After STZ injection, rats’ blood glucose levels, TC, and triglycerides significantly increased.&lt;strong&gt; Conclusion:&lt;/strong&gt; HFD feeding combined with a low-dose STZ effectively work to mimic specific condition that is similar to T2D, and the stability of the experimental animal conditions remains constant for up to 6 weeks.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6s</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">1562</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Raysa Y. Pratiwi&lt;sup&gt;1&lt;/sup&gt;, Berna Elya&lt;sup&gt;1&lt;/sup&gt;,&lt;sup&gt;*&lt;/sup&gt;, Heri Setiawan&lt;sup&gt;1&lt;/sup&gt;, Atini Solawati&lt;sup&gt;1&lt;/sup&gt;, Rosmalena&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Faculty of Pharmacy, Universitas Indonesia, Depok, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Faculty of Medicine, Universitas Indonesia, Depok, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mouchira Abdel Salam</style></author><author><style face="normal" font="default" size="100%">Hala M. Raslan</style></author><author><style face="normal" font="default" size="100%">Doha A. Mohamed</style></author><author><style face="normal" font="default" size="100%">Aliaa Elgendy</style></author><author><style face="normal" font="default" size="100%">Rehab A. Hussein</style></author><author><style face="normal" font="default" size="100%">Omneya Moguib</style></author><author><style face="normal" font="default" size="100%">Maha Abdelhadi</style></author><author><style face="normal" font="default" size="100%">Rokia Abd El-Shafy Soliman El-Banna</style></author><author><style face="normal" font="default" size="100%">Karem Fouda</style></author><author><style face="normal" font="default" size="100%">Safenaz Y. El Sherity</style></author><author><style face="normal" font="default" size="100%">Emad N. Zikri</style></author><author><style face="normal" font="default" size="100%">Nagwa M. Ammar</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of Soybean on Bone Health and Some Metabolic Parameters in Postmenopausal Egyptian Women</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Bone health</style></keyword><keyword><style  face="normal" font="default" size="100%">Bone mineral density</style></keyword><keyword><style  face="normal" font="default" size="100%">Hypocholesterolemic effect</style></keyword><keyword><style  face="normal" font="default" size="100%">Insulin resistance</style></keyword><keyword><style  face="normal" font="default" size="100%">Metabolic parameters</style></keyword><keyword><style  face="normal" font="default" size="100%">Soybean</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">May 2021</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">13</style></volume><pages><style face="normal" font="default" size="100%">688-697</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Great concern has been raised recently concerning the therapeutic impact of soybean. The present study aims to investigate the effects of soybean on bone health and metabolic parameters in postmenopausal women. &lt;strong&gt;Methods:&lt;/strong&gt; In this clinical study, 72 healthy postmenopausal women aged between 45-65 years were given soybean bioactive fraction 2 capsules (500mg each) daily for 24 weeks. Each capsule contained 31.25 mg proteins, 3.2 mg carbohydrates and 4.84 mg isoflavones. Blood pressure, bone mineral density, plasma osteocalcin (OCN), telopeptides of collagen type I (CTX), fasting insulin and blood glucose, lipid profile, serum creatinine, alanine transaminase (ALT), aspartate transaminase (AST), and TSH were assessed prior and after the period of the study. Insulin resistance was calculated by homeostatic model assessment-IR formula (HOMA-IR). &lt;strong&gt;Results:&lt;/strong&gt; Soy ingestion resulted in a significant increase in T score of the hip and OCN; recording -1.97±0.13/-1.76±0.12 and 22.44±0.60ng/ml/30.93±0.57ng/ml before/after treatment, respectively. A marked decrease was also detected in CTX from 2.22±0.10ng/ml to 1.48±0.08ng/ml. With regard to metabolic parameters, there was a significant decrease in fasting insulin (5.40±0.62uU/ml vs 4.15±0.45uU/ ml), however, fasting glucose and HOMA-IR showed no significant alterations. Lipid profile displayed remarkable decline in total cholesterol (188.86±7.23mg/dl vs 159.60±4.72mg/dl, triglycerides (97.09±5.23mg/dl vs 83.56±4.27mg/dl), LDL-c (75.60±3.06mg/dl vs 63.95±1.86mg/ dl) accompanied with a significant elevation in HDL-c (53.09±0.88 vs 65.81mg/dl±0.80mg/ dl). A significant decrease in both TSH (1.97±0.13 uIU/ml vs 1.40±0.08 uIU/ml) and serum creatinine (0.82±0.02mg/dl vs0.77±0.02mg/dl) was also noticed. &lt;strong&gt;Conclusion:&lt;/strong&gt; Consumption of soy improves bone health, reduces cardiovascular risk with no adverse effects on kidney, liver or thyroid functions.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">688</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Mouchira Abdel Salam&lt;sup&gt;1&lt;/sup&gt;, Hala M. Raslan&lt;sup&gt;2&lt;/sup&gt;, Doha A. Mohamed&lt;sup&gt;3&lt;/sup&gt;, Aliaa Elgendy&lt;sup&gt;1&lt;/sup&gt;, Rehab A. Hussein&lt;sup&gt;4,&lt;/sup&gt;*, Omneya Moguib&lt;sup&gt;2&lt;/sup&gt;, Maha Abdelhadi&lt;sup&gt;2&lt;/sup&gt;, Rokia Abd El- Shafy Soliman El-Banna&lt;sup&gt;5&lt;/sup&gt;, Karem Fouda&lt;sup&gt;3&lt;/sup&gt;, Safenaz Y. El Sherity&lt;sup&gt;5&lt;/sup&gt;, Emad N. Zikri&lt;sup&gt;1&lt;/sup&gt;, Nagwa M. Ammar&lt;sup&gt;3&lt;/sup&gt; &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Complementary Medicine Department, National Research Centre, Dokki, Cairo, EGYPT.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Internal Medicine Department, National Research Centre, Dokki, Cairo, EGYPT.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Nutrition and Food Sciences Department, National Research Centre, Dokki, Cairo, EGYPT.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Pharmacognosy Department, National Research Centre, Dokki, Cairo, EGYPT.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Biological Anthropology Department, National Research Centre, Dokki, Cairo, EGYPT.&lt;/p&gt;
</style></auth-address></record></records></xml>